ALVR Key Statistics, Chart & Performance
The current stock price of ALVR is 9.81 USD. In the past month the price increased by 2.51%. In the past year, price decreased by -43.32%.
ALVR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ALVR
Company Profile
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Company Info
ALLOVIR INC
1100 Winter Street
Waltham MASSACHUSETTS 02142 US
CEO: David Hallal
Employees: 8
Phone: 16174332605
ALLOVIR INC / ALVR FAQ
What does ALVR do?
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
What is the current price of ALVR stock?
The current stock price of ALVR is 9.81 USD. The price increased by 1.55% in the last trading session.
Does ALVR stock pay dividends?
ALVR does not pay a dividend.
How is the ChartMill rating for ALLOVIR INC?
ALVR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ALVR stock listed?
ALVR stock is listed on the Nasdaq exchange.
What sector and industry does ALLOVIR INC belong to?
ALLOVIR INC (ALVR) operates in the Health Care sector and the Biotechnology industry.
ALVR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALVR. When comparing the yearly performance of all stocks, ALVR is a bad performer in the overall market: 78.28% of all stocks are doing better.
ALVR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALVR. No worries on liquidiy or solvency for ALVR as it has an excellent financial health rating, but there are worries on the profitability.
ALVR Financial Highlights
Over the last trailing twelve months ALVR reported a non-GAAP Earnings per Share(EPS) of -1.67. The EPS increased by 25.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.57% | ||
| ROE | -51.87% | ||
| Debt/Equity | 0 |